Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety, reactogenicity, and immunogenicity data for the Modified Vaccinia Ankara (MVA) vaccine in hematopoietic stem cell tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• Modified Vaccinia Ankara (MVA) vaccine (Modified Vaccinia Ankara (MVA) vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Variola Major (Smallpox) | Phase 1 | Status: COMPLETED